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M2-polarized macrophages 
contribute to neovasculogenesis, 
leading to relapse of oral cancer 
following radiation
Makiko Okubo1, Mitomu Kioi1, Hideyuki Nakashima1, Kei Sugiura1, Kenji Mitsudo1, 
Ichiro Aoki2, Hideki Taniguchi3 & Iwai Tohnai1
Despite the fact that radiation is one of the standard therapies in the treatment of patients with oral 
cancer, tumours can recur even in the early stages of the disease, negatively impacting prognosis and 
quality of life. We previously found that CD11b+ bone marrow-derived cells (BMDCs) were recruited 
into human glioblastoma multiforme (GBM), leading to re-organization of the vasculature and tumour 
regrowth. However, it is not yet known how these cells contribute to tumour vascularization. In the 
present study, we investigated the role of infiltrating CD11b+ myeloid cells in the vascularization and 
recurrence of oral squamous cell carcinoma (OSCC). In a xenograft mouse model, local irradiation 
caused vascular damage and hypoxia in the tumour and increased infiltration of CD11b+ myeloid cells. 
These infiltrating cells showed characteristics of M2 macrophages (M2Mϕs) and are associated with 
the promotion of vascularization. M2Mϕs promoted tumour progression in recurrence after irradiation 
compared to non-irradiated tumours. In addition, we found that CD11b+ myeloid cells, as well as 
CD206+ M2Mϕs, are increased during recurrence after radiotherapy in human OSCC specimens. Our 
findings may lead to the development of potential clinical biomarkers or treatment targets in irradiated 
OSCC patients.
Surgery is standard therapy for the treatment of patients with oral cancer, even at advanced stages. However, 
chemo- and radiotherapy also play major roles in the treatment of advanced OSCC to avoid functional dis-
orders and cosmetic disturbances. Despite advances in treatment modalities, tumours may recur within the 
irradiated field, leading to a poor prognosis. Thus, improving local control of the primary tumour with radi-
otherapy would increase the cure rate of oral cancer. To that end, it is necessary to understand how tumour 
vasculature can be restored after irradiation, given that a local dose should eliminate existing tumour endothelial 
cells. Since Folkman proposed that tumours cannot grow beyond 2 to 3 mm in size without forming new blood 
vessels1, tumour angiogenesis has been a critical target of cancer therapy; substantial evidence has indicated 
that vascular endothelial growth factor (VEGF) plays an essential role in developmental angiogenesis. Although 
anti-angiogenic therapies with anti-VEGF antibodies and other VEGF inhibitors have been popular, their effect 
is often transitory, and tumours can regrow with increased aggressiveness following cessation of the treatment2,3. 
These data indicate that preventing angiogenesis is insufficient to inhibit tumour growth. Tumour vasculature is 
thought to be dependent on two principal factors. Angiogenesis is derived from the sprouting of endothelial cells 
from existing tumour vessels or nearby normal vessels1, and vasculogenesis is due to colonization of circulating 
endothelial progenitor cells (EPCs) or BMDCs4. Because tumour endothelial cells divide actively and are highly 
radiosensitive, it is unlikely that any of them could survive the doses given in a typical radiotherapy regimen. 
Thus, local irradiation may block the angiogenesis pathway, forcing tumour recurrence to rely on the vasculogen-
esis pathway.
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We have previously shown in an intracranial GBM xenograft model that irradiation induces recruitment of 
BMDCs into tumours, restoring radiation-damaged vasculature by vasculogenesis and thus allowing the growth 
of surviving tumour cells5. Kozin et al. also demonstrated in lung and breast tumour models that host-derived 
BMDC infiltration in tumours was stimulated by local irradiation and facilitates tumour recurrence through 
paracrine effects on irradiated tumour vasculature6. Both studies indicated that CD11b+ BMDCs, but not EPCs, 
make significant contributions to facilitate tumour regrowth after irradiation.
CD11b+ myeloid cells recruited into tumours are thought to subsequently differentiate into macrophages. 
Macrophages surrounding the tumour are referred to as tumour-associated macrophages (TAMs), which are 
believed to act as key regulators of tumour angiogenesis, migration, metastasis, and treatment resistance7. 
Macrophages are also polarized into two specific phenotypes in response to signals present within individ-
ual microenvironments. Pro-inflammatory M1Mϕ s (classically activated), which are activated by LPS and 
IFN-gamma, secrete TNF-alpha, IL-12, IL-6 and inducible NO synthase (iNOS) and support T-cell function. In 
contrast, M2Mϕ s (alternatively activated), which are activated by IL-4 and IL-13, produce IL-10 and TGF-beta 
and down-regulate T-cell function. M2Mϕ s are thought to be anti-inflammatory and immunosuppressive. M1 
and M2Mϕ s also have the ability to suppress and promote tumour progression, respectively8. Infiltrated TAMs in 
tumours are generally characterized as M2 phenotypes and promote tumour growth and vasculature9–11. Many 
clinical studies have also suggested a positive correlation between the number of TAMs and/or M2 profiles in a 
tumour and increased tumour angiogenesis and metastasis and poor prognosis in cancer patients12–16. Because 
monocytes should be polarized into macrophages in peripheral tissues, we hypothesized that CD11b+ myeloid 
cells recruited into irradiated tumours may be differentiated into a proangiogenic phenotype of macrophages. 
Therefore, our research aimed to investigate whether CD11b+ myeloid cells are recruited into oral cancer after 
irradiation and how they are differentiated into macrophages in relation to tumour relapse, which remains largely 
uncharacterized.
Results
Irradiation causes vascular damage and tumour hypoxia, leading to recruitment of CD11b+ 
myeloid cells into OSCC tumours. To assess alterations in the tumour microenvironment following radi-
otherapy, we established an OSCC xenograft mouse model using OSC-19 cells. As shown in Fig. 1a, s.c. implanted 
tumours grew progressively; however, 12 Gy local irradiation caused the tumours to regress, followed by regrowth 
in several weeks. Tumour samples following irradiation were collected when the tumours grew back to their 
pre-irradiation sizes and were analysed by immunofluorescence staining to compare the influx of CD11b+ cells 
with that of non-irradiated control tumours. We found that recurrences contained significantly higher numbers 
of CD11b+ cells (Fig. 1b,c). Similar results were obtained from other OSCC s.c. tumour models using HSC-3 
(tongue) and YCU-OR891 (oral floor) cells (Supplementary Fig. S1).
The results of previous reports5,17,18 suggested that CD11b+ cell recruitment was induced by hypoxia. To test 
this, we investigated hypoxia levels in tumours using pimonidazole staining along with blood vessel staining 
in a time course analysis. We found that hypoxic areas were extended in the tumours, starting from two weeks 
after irradiation, and CD31+ vascular endothelial cells were significantly reduced (Fig. 1d,e). Interestingly, fur-
ther analysis showed that the highest numbers of CD11b+ cells were recruited at the same time point and were 
inversely proportional to CD31 density (Fig. 1f,g). These data suggest that local tumour irradiation causes vas-
cular damage and hence tumour hypoxia, which may be the stimulus for the recruitment of CD11b+ cells into 
tumours.
Analysis of BMDC components in OSCC tumour-bearing mice. It was previously reported that 
monocyte precursors were increased in the BM, spleen and peripheral blood (PB) of tumour-bearing mice in 
various cancers19,20. Therefore, we first determined the proportion of CD11b+ cells in the PB and BM of normal 
mice and OSC-19 tumour-bearing mice by FACS analysis. In both the PB and the BM, the percentage of CD11b+ 
cells obtained from OSC-19 tumour-bearing mice was significantly higher than that of cells from normal mice 
(Fig. 2a,b). These data suggest that not only blood cells but also BMDCs may be altered by tumours, most likely 
by the secretion of cytokines and chemokines.
CD11b+ dominant BMDCs accelerate new blood vessel formation in tumours at the initial stage 
when tumours were injected. We then investigated whether BMDCs of OSC-19 tumour-bearing mice 
with higher numbers of CD11b+ cells affected cancer cell biology in vitro or tumour growth in vivo. To test this, 
OSC-19-luc cells were co-cultured with BMDCs of normal control mice or tumour-bearing mice, and the prolif-
eration of OSC-19-luc cells was assessed by the IVIS system. The results showed no significant difference between 
the control and tumour-bearing BMDCs with respect to OSC-19 cell proliferation, suggesting that in spite of 
different CD11b positive rates, BMDCs have no effect on OSC-19 cell proliferation (Fig. 3a).
We next examined the effect of BMDCs on the growth of OSC-19 s.c. tumours in nude mice. In this experi-
ment, BMDCs derived from normal control mice or tumour-bearing mice were co-injected with OSC-19 cells 
into non-IR or pre-IR sites, in which irradiation eliminated pre-existing blood vessels, causing the “tumour 
bed effect”21. Tumour nodules were initially formed at both non-IR and pre-IR sites when OSC-19 cells were 
injected with BMDCs of tumour-bearing mice. At non-IR sites, OSC-19 tumours injected with BMDCs of 
tumour-bearing mice grew progressively in the early stages of tumour growth. In contrast, the tumours with 
BMDCs of tumour-bearing mice grew progressively over the period of the experiment at the pre-IR site (Fig. 3b). 
We next examined blood vessel formation in the early stages of tumour growth in non-IR sites. We observed 
twice the density of CD31 endothelial cells in tumours when OSC-19 cells were co-injected with BMDCs of 
tumour-bearing mice as compared to those of normal control mice (Fig. 3c). These results suggest that CD11bhigh 
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Figure 1. Irradiation causes vascular damage and tumour hypoxia that promotes homing of BM-derived 
CD11b+ myeloid cells into OSCC tumours. (a) Growth curve of OSC-19 s.c. tumours treated with 12 Gy 
local irradiation on day 10. Data shown are means ± SEM, n = 4. (b) Representative images of IHC for CD11b 
staining in OSC-19 s.c. tumours before and after irradiation. Scale bars: 50 μ m. (c) Quantification of CD11b 
cell influx into the tumour. Data shown are means ± SD. ** P < 0.01. (d) Representative images of IHC staining 
for CD31+ vascular endothelial cells and pimonidazole+ hypoxic areas in OSC-19 tumours two weeks after 
12 Gy irradiation. Scale bars: 75 μ m. (e) Quantification of vessels and hypoxic areas in the tumour following 
irradiation. Data shown are means ± SD. * P < 0.05; ** P < 0.01; *** P < 0.001 versus control. (f ) IHC staining for 
CD11b+ cells and CD31+ vascular endothelial cells in OSC-19 tumours two weeks after 12 Gy irradiation. Scale 
bars: 75 μ m. (g) Quantification of CD11b+ cells and vessels in the tumour following irradiation. Data shown are 
mean ± SD. * P < 0.05; ** P < 0.01; *** P < 0.001 versus control. IR, irradiation.
www.nature.com/scientificreports/
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BMDCs derived from tumour-bearing hosts may stimulate new blood vessel formation in the initial stage, when 
tumours have limited blood supply.
M2Mϕs are polarized from CD11b+ myeloid cells in OSC-19 tumours after irradiation. We next 
characterized the CD11b+ cells recruited into tumours after irradiation. Double immunostaining with CD11b 
and F4/80, Gr-1, Tie-2 or VEGFR2 revealed that CD11b+F4/80+ cells were the most common population, fol-
lowed by CD11b+Gr-1+ cells. Subsets of CD11b+ cells, however small the number, expressed Tie-2 antigen, 
categorizing them as Tie2-expressing macrophages (TEMs). TEMs have been reported to be highly proangio-
genic and to interact with the formation of tumour blood vessels22. CD11b+VEGFR+ circulating precursor cells 
that contribute to the structural luminal surface of capillaries were not detectable. These results indicate that 
recruited CD11b+ cells are highly related to the macrophage lineage (Fig. 4a,b). We then analysed the charac-
teristics of the macrophage lineage recruited in tumours. We found that CD68+CD206+ M2Mϕ s were mainly 
localized in peritumoural areas and that their number in tumours after irradiation was significantly higher than 
those in non-irradiated controls (Fig. 4c,d). We next analysed the number of M1 or M2Mϕ s in tumours, as 
shown in Fig. 3c. While M2Mϕ s were significantly induced in OSC-19 tumours co-injected with the BMDCs 
of tumour-bearing mice compared to that of normal mice, the number of M1Mϕ s was not significantly affected 
(Fig. 4e). Furthermore, most of the CD68+CD206+ M2Mϕ s co-expressed CD11b antigen (Fig. 4c), indicating that 
recruited CD11b+ cells induced by irradiation are polarized into M2Mϕ s, resulting in contributions to tumour 
progression.
M2Mϕs may regulate tumourigenicity in tumour regrowth. To examine the function of M1 
and M2Mϕ s in tumour growth and regrowth following irradiation, we first confirmed the induction of mac-
rophage polarization in WEHI274.1 cells and BM-Mϕ s obtained from nude mice. Cells were incubated with 
various cytokines to induce differentiation into M1 or M2Mϕ s. RT-PCR showed that IFN-γ /LPS and IL-4/IL-13 
stimulation induced the polarization of M1 and M2Mϕ s, respectively (Fig. 5a). We next investigated whether 
BM-M1Mϕs and BM-M2Mϕ s can influence OSC-19 cell proliferation in vitro. OSC-19-luc cells were incu-
bated with BM-M1Mϕ s or BM-M2Mϕ s, and cell proliferation was assessed by the IVIS system. As shown in 
Supplementary Fig. S2, there was no significant difference in OSC-19 cell proliferation between the M1 and 
M2Mϕ s-co-cultured groups, suggesting that neither M1 nor M2Mϕ s had an effect on OSC-19 cell proliferation. 
We next examined the effect of these cells on tumour growth in vivo. We injected OSC-19 cells into non-IR or 
pre-IR sites alone or in the presence of BM-M1Mϕ s or BM-M2Mϕ s (Supplementary Fig. S3). Tumour growth 
Figure 2. The proportion of CD11b+ cells in PB and BM of normal mice and OSC-19 tumour-bearing 
mice. (a) PB was prepared by collecting whole blood from normal mice and OSC-19 tumour-bearing mice and 
eliminated red blood cells. CD11b positive rate in PB was comparative analysed by FACS. (b) BM was prepared 
from normal mice and OSC-19 tumour-bearing mice as previously described in Methods. CD11b positive rate 
in BM was comparatively analysed by FACS. Data shown are means ± SD. n = 6–8 per group, ***P < 0.001. PB, 
peripheral blood; BM, bone marrow.
www.nature.com/scientificreports/
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with BM-M2Mϕ s was promoted until day 18 in the non-IR site. Tumour growth at the pre-IR site was signifi-
cantly accelerated in the presence of BM-M2Mϕ s over a long period compared to BM-M1Mϕ s or even tumour 
cells alone (Fig. 5b). As shown in Fig. 5c, tumours with BM-M2Mϕ s at non-IR sites appeared haemorrhagic; 
therefore, we examined blood vessel formation. CD31+ vessel cells were significantly increased in tumours when 
OSC-19 cells were co-injected with BM-M2Mϕ s compared to controls (Fig. 5d). Furthermore, we investigated the 
role of BM-M2Mϕ s in blood vessel formation without cancer cells. As shown in Fig. 5e and Supplementary Fig. 
S4, BM-M2Mϕ s promoted tube-like formation in CD31+ endothelial cells in a Matrigel plug assay in nude mice 
compared with controls. These results suggest that BM-M2Mϕ s enhance tumourigenicity by promoting tumour 
vasculature, especially when local endothelial cells are eradicated by irradiation.
The portion of CD11b+ myeloid cells and M2Mϕs recruited into tumours after irradiation 
expresses IL-13Rα2. IL-13Rα 2, one of the IL-13 receptors, is highly expressed in some cancer cells, includ-
ing GBM23 and OSCC24; therefore, targeting this receptor, such as CAR-T and IL13-PE, would be new strategy for 
these cancer patients25. Interestingly, recent reports have shown that macrophages recruited by inflammation in 
ulcerative colitis and pulmonary fibrosis also express IL-13Rα 226,27. We therefore investigated whether CD11b+ 
Figure 3. CD11b+ dominant BMDCs may stimulate blood vessels formation and promote tumour growth. 
(a) OSC-19-luc cells (4 or 8 × 103 cells) were co-cultured with BMDCs (8 × 103 cells) of normal mice or OSC-
19 tumour-bearing mice in 24-well plates in quadruplicate. Bioluminescent signals were determined using the 
IVIS system on the indicated date. Data shown are means ± SD. (b) OSC-19 cells (2 × 106 cells) were co-injected 
with BMDCs (2 × 106 cells) of normal mice or OSC-19 tumour-bearing mice into non-IR or pre-IR sites of 
nude mice. Tumour size was measured on the indicated date. Data shown are means ± SEM, n = 5–7 per group. 
*P < 0.05; *** P < 0.001. (c) Quantification of CD31 density of IHC in the early stage (day10) of the tumour at 
non-IR site. Data shown are means ± SD. *** P < 0.001. Non-IR, non-irradiated; Pre-IR, previously-irradiated; 
BMDC, bone marrow-derived cell.
www.nature.com/scientificreports/
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cells and M2Mϕ s recruited into tumours following irradiation express IL-13Rα 2. To test our hypothesis, we 
examined the expression levels of IL-13Rα 2 in M1 and M2Mϕ s derived from WEHI274.1 cells and BMDCs. 
RT-PCR showed higher levels of IL-13Rα 2 expression in both M2Mϕ s (Fig. 5f). Furthermore, we compared 
the IL-13Rα 2 expression in CD11b+ cells recruited into OSC-19 tumours at non-IR and pre-IR sites by FACS 
analysis. Interestingly, the percentage of IL-13Rα 2+ cells in CD11b+ cells in tumours grown at pre-IR sites was 
significantly higher than that of non-IR sites (Fig. 5g). These results suggest that IL-13Rα 2 is a potent molecular 
target for the depletion or ablation of CD11b+ cells and for M2Mϕ s to inhibit reorganization of blood vessels 
following radiation.
Figure 4. Characterization of CD11b+ infiltrating cells into OSC-19 tumours after irradiation.  
(a) Representative images of IHC for DAPI (blue), CD11b (red), and other markers (Gr-1 or F4/80: green) 
in OSC-19 tumours two weeks after irradiation. Scale bar: 50 μ m. (b) Quantification of positive staining 
for VEGFR2, Tie-2, Gr-1, or F4/80 co-stained with CD11b. Data shown are means ± SD. *** P < 0.001. (c) 
Representative images of IHC for CD68+CD206+ M2Mϕ s and CD11b+ cells in OSC-19 tumours two weeks 
after irradiation. Scale bar: 50 μ m. (d) Quantification of M2Mϕ s localized in peritumoural areas. Data shown 
are means ± SD. * P < 0.05. (e) Quantification of CD68+iNOS+ M1Mϕ s and CD68+CD206+ M2Mϕ s in the 
tumours of Fig. 3c. Data shown are means ± SD. * P < 0.05. Mϕ s, macrophages; BMDC, bone marrow-derived 
cell.
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CD11b+ myeloid cells and M2Mϕs are increased in recurrences of human OSCC clinical sam-
ples. To determine the potential clinical relevance for patients with OSCC, we validated our findings from 
Figure 5. M2Mϕs enhance tumourigenicity by accelerating tumour vascularization. (a) RT-PCR showed 
that 24-hours of stimulation with IFN-γ /LPS and IL-4/IL-13 induced the polarization of WEHI274.1 cells and 
BM-Mϕ s into M1 and M2Mϕ s, respectively. (b) OSC-19 cells (2 × 106 cells) were co-injected with BM-M1Mϕs 
or BM-M2Mϕ s (1 × 106 cells) into non-IR or pre-IR sites of nude mice. Tumour size was measured on the 
indicated date. Data shown are means ± SEM, n = 4–5 per group. ** P < 0.01, *** P < 0.001. (c) The photographs 
were taken on day 15 after tumour implantation into non-IR site. (d) Quantification of CD31 density of IHC in 
the early stage (day 16) of the tumour at non-IR site. Data shown are means ± SD. * P < 0.05. (e) BM-M2Mϕs 
increased the number of CD31 endothelial cells in Matrigel plugs in vivo. Data shown are means ± SD, n = 4 
per group. * P < 0.05. (f) RT-PCR showed higher expression of IL-13Rα 2 in M2Mϕ s derived from WEHI274.1 
cells and BMDCs rather than M1Mϕ s. (g) FACS analysis showed that IL-13Rα 2 expression in CD11b+ cells 
recruited into tumours grown at pre-IR sites was significantly higher than that at non-IR sites. Data shown are 
means ± SD, n = 6 per group. *** P < 0.001. BM-Mϕ , bone marrow-derived macrophage.
www.nature.com/scientificreports/
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a mouse model in humoral tumour tissue specimens. Immunohistochemical analyses were performed using 
human OSCC specimens obtained from biopsy samples before treatment and from recurrent tumours after 
radiotherapy in the same individuals. We found higher levels of CD11b+ cells in the recurrent tumours than 
in the untreated primary tumours in eight out of eleven paired samples (Fig. 6a,b). We then further evaluated 
the expression of CD31, CD68, and CD206 in the same specimens and found that CD206+ M2Mϕ s was also 
increased in recurrences, while the recurrent tumours showed lower levels of CD31 vasculature (Fig. 6c).
Discussion
The present study demonstrated that local irradiation promotes the influx of CD11b+ myeloid cells into OSCC, 
followed by polarization towards M2Mϕ s, contributing to re-organization of the vascular network in the tumour. 
Data presented herein show for the first time that irradiation induces CD68+CD206+ M2Mϕ s polarization that 
promotes neovascularization in OSCC in a mouse model.
We have shown that irradiation induces recruitment of CD11b+ BMDCs into OSCC. This is consistent with 
previous studies showing that an increased influx of CD11b+ cells was found in irradiated tumours in several can-
cer models6,15,28. We also previously reported in GBM specimens that there was a significant increase in CD11b+ 
cell infiltration in recurrent tumours compared with their matched primary tumour specimens, which is consist-
ent with our current OSCC data. The stimulus for this phenomenon is that increased tumour hypoxia occurred 
due to the loss of blood vessels. Hypoxia-inducible factor-1α (HIF-1α ) is a crucial factor in the induction of 
BMDC influx. Various animal studies showed that HIF-1α regulates many chemokines that may induce recruit-
ment of BMDCs into tumours, including chemokine ligand 2 (CCL2 or MCP1)29, colony-stimulating factor-1 
(CSF-1)30–32, and stromal-derived factor-1 (SDF-1)5,17. The present study also demonstrates that hypoxia is prom-
inently increased in OSC-19 tumours as it initiates recruitment of CD11b+ cells into the tumour.
Previous studies reported that CD11b+ monocyte precursors were increased in the BM, spleen, and PB of 
tumour-bearing mice in colon adenocarcinoma, mammary adenocarcinoma, and lymphoma. Moreover, those 
immature myeloid cells are also further produced in the PB of patients with cancer19,20. The increases in these cells 
in the PB are thought to be due to release from the BM by cytokines and chemokines secreted by tumour cells. We 
Figure 6. Immunohistochemical analyses of human OSCC clinical specimens. (a) Representative staining  
for CD11b expression in OSCC clinical samples obtained from primary and recurrent tumours.  
(b) Quantification of CD11b based on IHC with CD11b staining. Increased numbers of CD11b+ cells in 
recurrent human OSCCs were seen in eight of eleven samples. * P < 0.05. (c) Representative staining for CD31, 
CD68, and CD206 expression in OSCC clinical samples obtained from primary and recurrent tumours.
www.nature.com/scientificreports/
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also found a higher proportion of CD11b+ cells in the PB and BM of OSC-19 tumour-bearing mice, suggesting 
that BMDCs can be altered by tumours, likely secretory cytokines and chemokines.
BMDC accumulation in OSC-19 tumours after local irradiation was largely composed of CD11b+ myeloid 
cells. Subclass analyses of these cells showed high co-expression of F4/80, indicating that they are of the mac-
rophage lineage. TEMs, which have shown the proangiogenic activity of myeloid cells in tumours, were small 
in number, which is consistent with a previous report22. De Palma et al. demonstrated in mouse xenografts 
that conditional depletion of TEMs prevented angiogenesis and delayed tumour growth. We also reported that 
approximately half of the CD11b+ myeloid cells recruited into the irradiated GBM were TEMs5. Inhibiting TEM 
recruitment into tumours by pharmacologically interfering with the CXCL12/CXCR4 axis increased the efficacy 
of radiation or vascular-disrupting agents in GBM and murine mammary tumours5,33. However, inhibition of 
CXCL12 by AMD3100 had no effect on the regrowth of OSC-19 tumours after irradiation (data not shown), indi-
cating that the proportion of TEMs and chemokine for recruitment is likely different from the types of histology, 
advancement, or location of the tumours. CD11b+Gr-1+myeloid cells, known as myeloid-derived suppressor cells 
(MDSCs), that have been reported accumulate in several tumours, suppress tumour immunity and thus promote 
tumour growth34. In our study, the amount of MDSC accumulation in tumours was significantly increased after 
irradiation, but not as much as in CD11b+F4/80+ cells. Moreover, Ahn et al. suggested that CD11b-neutralizing 
antibodies enhanced tumour responsiveness to radiation in transplanted tumours, whereas depletion of Gr-1+ 
cells did not show the same effect. Although the possible involvement of CD11b+Gr-1-Ly-6Chi monocytic MDSCs 
in tumour relapse after radiation may not be excluded, CD11b+ monocytic cells, but not CD11b+ neutrophils or 
granulocytes, seem to be more critical as a proangiogenic population28.
M2Mϕ s have been reported to have protumoural functions, including functions in angiogenesis and altera-
tions in invasiveness. In our study, M2Mϕ s had no effect on OSC-19 cell proliferation in vitro, while they pro-
moted tumour growth and regrowth in vivo. This effect was more significant and lasted much longer in tumours 
injected at pre-IR sites. CD31 endothelial cells in the tumours of non-IR sites showed that OSC-19 tumours 
injected with M2Mϕ s formed more blood vessels. These results suggested that the effect of M2Mϕ s on neovascu-
larization acts in more ischaemic conditions and contributes to relapse in OSCC tumours. Indeed, in conditions 
such as wound and ischaemic heart disease models, polarization of the M2 phenotype is promoted in infiltrating 
macrophages. Oxygen deprivation functionally links to progressive induction of proangiogenic M2Mϕ s35.
We have previously reported in a GBM model that tumour vascularization mainly relies on angiogenesis in 
normal conditions; however, when local irradiation inhibits angiogenesis and induces hypoxia, vasculogenesis 
predominates. In this study, CD31 endothelial cells decreased to 36% of control levels by 2 weeks after 12 Gy irra-
diation so that angiogenesis was inhibited by irradiation in an OSCC model. Because BMDCs of tumour-bearing 
mice also promoted tumour growth in non-IR sites, it is possible that angiogenesis was also stimulated. However, 
the effect of tumour-bearing BMDCs was limited to the initial stage of non-IR tumours and was more significant 
in pre-IR sites; therefore, BMDCs more likely contribute to vasculogenesis in irradiated tumours. Proangiogenic 
M2Mϕ s are reported to secrete several angiogenic factors, such as VEGF, IL-8 (CXCL8), bFGF (basic fibroblast 
growth factor), TP (thymidine phosphorylase), and MMP (matrix metalloproteinase)11,36, recolonizing and sta-
bilizing tumour vasculature after irradiation, thereby supporting any remaining viable tumour cells. However, the 
specific mechanism underlying this process is not well understood, and further studies will be necessary.
The observation of increased CD11b+ myeloid cells in recurrence also has clinical implications. Evidence 
has accumulated suggesting that recruitment of myeloid cells into tumours is correlated with clinical outcomes 
accompanied by treatment. A previous study reported that macrophage density positively correlated with 
microvessel counts and negatively correlated with patient relapse-free survival in lung cancer37. Balermpas et al. 
also reported that CD163+ macrophage expression predicts an unfavourable clinical outcome in HNSCC after 
definitive chemoradiotherapy15. In the present study, CD206+ M2Mϕ s was also increased in recurrences of OSCC 
specimens after radiotherapy. These results suggest that increased myeloid cells or TAMs in tumours or PB may 
be independent prognostic markers. Local and distant recurrence occurs in approximately 30% of OSCC. Hence, 
it is crucial to identify novel biomarkers that predict patients at high risk of relapse.
Although several TAM-targeting cancer therapies have been explored, whole TAM depletion may also affect 
monocyte/macrophage-mediated host defence. Therefore, a M2Mϕ s-specific targeting agent would need to exert 
high anti-tumour effects with radiation while minimizing toxicity38. To our knowledge, there are very few meth-
ods of specific molecular targeting for M2Mϕ s. Cieslewicz et al. developed a unique peptide called M2pep that 
preferentially binds to M2Mϕ s, including TAMs39. In this study, we found that M2Mϕ s polarized after radia-
tion highly expressed IL-13Rα 2; therefore, this molecule would be a promising target as a new strategy com-
bined sequentially with radiotherapy. It has been demonstrated that IL13-PE composed of IL-13 and truncated 
Pseudomonas exotoxin (PE) directly killed IL-13Rα 2 positive cells40. Therefore, IL13-PE has the potential to gen-
erate synergistic antitumour effects, directly killing tumour cells and specifically ablating protumoural M2Mϕ s.
In summary, our data suggest that local irradiation induces recruitment of CD11b+ myeloid cells into OSCC 
and that these are polarized towards M2Mϕ s shortly before tumours start to regrow. M2Mϕ s rather than CD11+ 
myeloid cells may contribute to neovasculogenesis and relapse in OSCC after radiation.
Methods
Cell lines. OSC-19 and HSC-3 cell lines (human squamous cell carcinoma of the tongue) were purchased 
from the Japanese Collection of Research Bioresources. YCU-OR891 cells (human squamous cell carcinoma 
of the oral floor) were obtained from Dr. Oridate of Yokohama City University. OSC-19-luc cells were retrovi-
rally transduced with the luciferase gene, as previously described5. The WEHI274.1 cell line (murine monocyte) 
was obtained from Dr. JM Brown (Stanford University). Cells were maintained in PRMI1640 (YCU-OR891) or 
DMEM (all other cells) containing 10% foetal bovine serum (FBS). All subsequent experiments were approved by 
the Ethics Committee of Yokohama City University (registration number B100513003).
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Animals. Female 4–7-week-old BALB/c nude mice weighting 14–18 g were purchased from SLC Japan. 
All studies were conducted in accordance with protocols approved by the Institutional Animal Care and Use 
Committee at Yokohama City University.
Isolation of BMDCs. BMDCs were harvested by flushing the femurs and tibias of female BALB/c nude mice 
with RPMI1640 Glutamax (Thermo Fisher Scientific) supplemented with 10% FBS using a 25G needle and a 
syringe. BMDCs were passed through a 70 μ m cell strainer, and red blood cells were removed by NH4Cl solution. 
BMDCs of OSC-19 tumour-bearing mice were obtained from female BALB/c nude mice previously implanted 
with OSC-19 cells.
Cytokine-stimulated macrophage phenotypic polarization. For BMDC differentiation into 
BM-derived macrophages (BM-Mϕ s), BMDCs were cultured for an additional 7 days in the same medium 
supplement with 10 ng/ml recombinant macrophage colony-stimulating factor (M-CSF) (Peprotech). The 
efficiency of differentiation was confirmed by FACS analysis for CD11b and F4/80 antigen surface expression 
(Supplementary Fig. S5). To induce the macrophage phenotypic polarization, WEHI274.1 cells and BM-Mϕ s 
were treated for 24 hours with 100 ng/ml IFN-γ (Peprotech) or 200 ng/ml LPS (SIGMA) for M1Mϕ s and 20 ng/
ml IL-4 (R&D systems) or 20 ng/ml IL-13 (Miltenyi Biotec) for M2Mϕ s.
Reverse transcription-PCR. Total RNA was isolated using RNeasy, and reverse transcription was per-
formed using SuperScriptTMIII Reverse Transcriptase (Thermo Fisher Scientific). PCR with TaKaRa Ex Taq 
(Takara) was performed with primers (Sigma Genosys), as shown in Supplementary Table S141–45. PCR products 
were viewed using Dolphin-View DV-18 (Kurabou).
Co-culture study. For two co-culture studies, OSC-19-luc cells were plated in 24-well plates with or with-
out BMDCs of normal control mice or OSC-19 tumour-bearing mice and with or without BM-derived M1Mϕ s 
(BM-M1Mϕ s) or BM-derived M2Mϕ s (BM-M2Mϕ s) at indicated ratios. Then, proliferation of OSC-19-luc cells 
was assessed via the enzymatic activities of luciferase using the IVIS system (IVIS Lumina II ver.4, Caliper) on 
the indicated date.
Xenograft tumour mouse model and irradiation. OSC-19 cells (3 × 106 cells) were subcutaneously 
(s.c.) implanted on the back of a female BALB/c nude mouse. Tumour volume (V) was calculated with callipers 
as V = L × W2 × 0.5 (L, length; W, width). When the tumour volume reached approximately 200 mm3, 12 Gy of 
local irradiation was administered (HITACH X-ray MBR-1520-4) using a specialized lead jig. For the pre-IR 
model, 12 Gy of irradiation was performed before tumour implantation. For the two co-injection studies, OSC-
19 cells with or without BMDCs of normal control mice or OSC-19 tumour-bearing mice were s.c. injected into 
non-irradiated (non-IR) or pre-IR sites. For the other experiment, OSC-19 cells were injected with or without 
BM-M1Mϕ s or BM-M2Mϕ s.
Immunofluorescence staining for mouse sample. Tumour samples were fixed by 4% paraformalde-
hyde cardiac perfusion and then embedded in OCT compound (Sakura Finetek). Frozen sections (5–10 μ m) were 
incubated with the following primary anti-mouse antibodies overnight at 4 °C: CD31 (BD Bioscience), CD11b 
(BioLegend), Tie-2, F4/80, Gr-1 (eBioscience), VEGFR2 (R&D Systems), CD68 (Serotec), CD206 (Santa Cruz) 
and iNOS (Abcam). They were then incubated with secondary antibodies for 30 min at room temperature, includ-
ing Alexa Flour 488, 546, Streptavidin labeled with Alexa Flour 488, 546 and 647 (Thermo Fisher Scientific). 
Hypoxic areas were detected using pimonidazole hydrochloride staining (HypoxyprobeTM-1 Omni kit, Natural 
Pharmacia International) according to the manufacturer’s instructions. All sections were mounted in ProLong® 
Gold Antifade Mountant with DAPI (Thermo Fisher Scientific) and imaged with Leica DMI 4000B fluorescent 
microscopy (Leica Microsystems Inc.). Isotype-matched IgG was used as a negative control.
Immunohistochemistry for human samples. Human OSCC specimens of primary tumours and 
matched recurrences after chemoradiotherapy were obtained from the same individuals by biopsy or surgi-
cal resection at the Department of Oral and Maxillofacial Surgery in Yokohama City University Hospital after 
obtaining informed consent from all subjects. The protocol to use tissue samples for this study was approved by 
Yokohama City University School of Medicine in accordance with the principles of the Declaration of Helsinki. 
Paraffin-embedded sections were incubated with anti-human CD11b, CD31, CD206 (Abcam) and CD68 (Dako) 
overnight at 4 °C. The reaction was visualized with the Vector Stain ABC kit and ImPACT DAB Substrate (Vector 
Laboratories). Sections were counterstained with haematoxylin and viewed with an OLYMPUS BH2 microscope 
(Olympus).
Matrigel Plug assay. Matrigel (growth factor reduced phenol red-free, Corning; 450 μ l) supplemented 
with 75 ng of basic fibroblast growth factor (bFGF) (Peprotech) was mixed with BM-M2Mϕ s (1 × 106 cells) and 
injected into the flank of female BALB/c nude mice. Matrigel with bFGF served as a control. One week after 
inoculation, Matrigel plugs were surgically removed, and frozen sections were analysed by immunofluorescence 
staining for the presence of CD31 endothelial cells.
Quantification of expression. Quantitative analyses for CD11b, Tie-2, F4/80, Gr-1, VEGFR2, CD68, 
CD206, iNOS and CD31 were performed by determining the number of positive cells. The signal density of CD31 
and pimonidazole were measured using Image J. All analyses were performed in at least three randomly photo-
graphed fields using the ×20 or ×40 objectives and ×10 eyepieces of the fluorescence microscope. Three to eight 
animals per group were used; the error bars shown in the figures indicate SD or SEM.
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Flow cytometric analysis. Mouse whole blood was collected with 1.5% EDTA-2Na used as the antico-
agulation agent, and red blood cells were eliminated by a lysing buffer (BD Pharmingen). Leukocyte cells and 
BMDCs of normal control mice or OSC-19 tumour-bearing mice were stained with CD11b-PE antibody (BD 
Pharmingen). For IL-13Rα 2 and CD11b double staining, OSC-19 tumours grown at non-IR sites or pre-IR sites 
in nude mice were minced and enzymatically digested with 3 mg/ml Type VI collagenase and 2 U/ml hyaluroni-
dase (SIGMA). They were further treated with 0.1 mg/ml DNase I (Wako) and 0.09% NH4Cl and strained through 
a 40 μ m cell strainer. Single cells were incubated with IL-13Rα 2-biotin (R&D systems) and CD11b-PE antibodies 
(BD Pharmingen), followed by Streptavidin-APC antibody (eBioscience). All samples were pre-incubated with 
Fc-block (BioLegend) prior to staining. Analysis was performed using MoFlo® Astrios (Beckman Coulter) and 
Summit Software ver. 4.3 (Beckman Coulter).
Statistical Analysis. Statistical analyses for multiple-group comparison were analysed by one-way ANOVA. 
For two-group comparisons, Student’s t-test was used (GraphPad Prism software version 5.02). P values (exact 
significance) less than 0.05 were considered statistically significant.
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Supplementary Figure S1.  
The representative images of IHC for CD11b+ myeloid cells in OSCC tumours 
before and after irradiation. HSC-3 cells (1×107 cells) and YCU-OR891 cells (3×106 
cells) were s.c. implanted on the back of female BALB/c nude mice, and grown tumours 
were irradiated in a manner similar to the OSC-19 model. Tumour samples were stained 
with CD11b antibody.  
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Supplementary Figure S2. 
Co-culture experiment of OSC-19-luc cells and BM-M1Mφs or BM-M2Mφs. 
OSC-19-luc cells (6×103 cells) were co-cultured with BM-M1Mφs or BM-M2Mφs (1.5 
or 6×103 cells) in 24 well plates in quadruplicate. Bioluminescent signals were 
determined using the IVIS system on indicated date. Data shown are means ± SD. 
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Supplementary Figure S3.  
Pattern diagram of the experimental design for co-injection of OSC-19 cells and 
BM-M1Mφs or BM-M2Mφs. OSC-19 cells were injected into non-IR or pre-IR sites 
alone or in the presence of BM-M1Mφs or BM-M2Mφs previously prepared in vitro. 
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Supplementary Figure S4. 
Representative image of Matrigel Plug assay. BM-M2Mφs promoted tube-like 
formation of CD31+ endothelial cells (red) in Matrigel plug.  
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Supplementary Figure S5. 
FACS analysis of BMDCs and BM-Mφs. FACS analysis showed that CD11b+F4/80- 
BMDCs harvested from BALB/c nude mice differentiated into CD11b+F4/80+ BM-Mφs 
by extended culture with M-CSF for 7 days. BMDC, bone marrow-derived cell; 
BM-Mφs, bone marrow-derived macrophages; M-CSF, macrophage colony-stimulating 
factor. 
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Supplementary Table S1.  
Primer sequences specification for RT-PCR. 
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